Physician profile
Olamipo Odebode
NPI 1770066623
$3,363.17
in general payments reported to CMS, 2019-2025
20 companies · $98.65 in 2025
The $98.65 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $603 · 2022: $878 · 2023: $860 · 2024: $924 · 2025: $98.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.55 |
| Education | $138.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $538.68 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $457.91 | 2021-2023 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $375.62 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $286.53 | 2022-2024 | Austedo Xr, Austedo |
| Lundbeck LLC | $268.19 | 2022-2024 | Brintellix, Rexulti |
| Alkermes, INC. | $263.58 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $260.59 | 2021-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $210.18 | 2021-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $120.75 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $112.35 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $98.90 | 2022-2024 | Spravato |
| Avanir Pharmaceuticals, INC. | $76.76 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.41 | 2021-2022 | |
| Corium, LLC | $48.85 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $47.37 | 2023-2024 | Qelbree, Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $33.38 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $31.47 | 2021-2022 | |
| Tempus Ai, INC | $24.06 | 2024 | |
| Bausch Health US, LLC | $23.41 | 2021 | |
| Eisai INC. | $17.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olamipo Odebode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.